Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI). Investors who purchased Brainstorm securities are encouraged to obtain additional information and assist the investigation.   

 

The investigation concerns whether Brainstorm violated federal securities laws.

 

On November 10, 2022, Brainstorm issued a press release announcing that the Company had received a refusal to file letter from the United States Food and Drug Administration (“FDA”) for its New Biologics License Application for NurOwn for the treatment of Amyotrophic lateral sclerosis.  The press release disclosed that investigators of the NurOwn Phase 3 study jointly stated “the pre-specified primary outcome measure was not met.”  The press release further stated that FDA has indicated that the Company can request a Type A meeting to discuss the content of the refusal to file letter.  On this news, Brainstorm’s stock price fell sharply during intraday trading on November 10, 2022.

 

If you are aware of any facts relating to this investigation or purchased Brainstorm securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

 

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.